Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

Jun 23, 2013 8:30 AM - Jun 27, 2013 12:45 PM

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

Approaches to Quality Risk Management: Understanding What Matters

Session Chair(s)

Martin  Landray, PhD, FRCP

Martin Landray, PhD, FRCP

Chief Executive

Protas, United Kingdom

This forum will review the Clinical Trials Transformation Initiative’s (CTTI) potential methods to apply principles of Quality by Design and quality risk management to the scientific and operational design of clinical trials.

Learning Objective : Discuss the workshops on quality risk management; Describe general principles for building quality into the design of trials; Identify benefits and obstacles to the adoption of this approach based on feedback from CTTI workshop participants.

Speaker(s)

Martin  Landray, PhD, FRCP

What Are the Key Drivers for Quality?

Martin Landray, PhD, FRCP

Protas, United Kingdom

Chief Executive

Mark  Behm

Quality Risk Assessment and Quality by Design: Principles Not Jargon

Mark Behm

Astrazeneca, United States

Sr Director Procedural Quality

Ann  Meeker-O'Connell, MS

Regulatory Requirement for Ensuring Quality: A US Perspective

Ann Meeker-O'Connell, MS

FDA, United States

Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.